Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- momelotinib
- Pamine FQ (lactobacillus acidophilus / methscopolamine)
Interactions between your drugs
lactobacillus acidophilus momelotinib
Applies to: Pamine FQ (lactobacillus acidophilus / methscopolamine), momelotinib
If you are currently being treated or have recently been treated with momelotinib, you should let your doctor know before using lactobacillus acidophilus. Depending on the dose and length of time you have been on momelotinib, you may be at risk for developing rare infections from exposure to products containing live bacteria or yeast. Depending on your overall health and medical condition, it may be advisable to avoid using lactobacillus acidophilus until your immune system has recovered from the effects of momelotinib. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food/lifestyle interactions
methscopolamine food/lifestyle
Applies to: Pamine FQ (lactobacillus acidophilus / methscopolamine)
Ask your doctor before using methscopolamine together with ethanol (alcohol). Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while you are taking methscopolamine. You should be warned not to exceed recommended dosages and to avoid activities requiring mental alertness. If your doctor prescribes these medications together, you may need a dose adjustment to safely take this combination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Ojjaara
Ojjaara (momelotinib) may be used to treat adults with certain types of myelofibrosis (MF) who have ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Vonjo
Vonjo (pacritinib) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Inrebic
Inrebic is used to treat certain types of myelofibrosis (MF) in adults. It is an oral capsule taken ...
Fedratinib
Fedratinib is used for certain types of myelofibrosis (MF) in adults, relieving night sweats ...
Pacritinib
Pacritinib (brand name Vonjo) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.